Treatment of many cancers relies on the combined action of several genotoxins, but the detrimental effect of these drugs on normal cells can cause severe side effects. One major challenge in anticancer therapy is therefore to increase the selectivity of current treatments toward cancer cells in order to spare normal cells. We have recently demonstrated that a RasGAP caspase cleavage fragment is able to sensitize HeLa cells towards cisplatininduced apoptosis. Here, we extend this observation by showing that this fragment also enhances cell death induced by adriamycin and mitoxantrone, two other widely used genotoxins. Furthermore, we have delineated a short sequence within this fragment that still bears the genotoxin-sensitization property. The peptide encoded by this sequence, when fused to the TAT cell permeation sequence, potently sensitized a number of tumors cells, but not normal cells, towards apoptosis induced by cisplatin, adriamycin and mitoxantrone. This sensitization effect was not mediated through modulation of NFjB activity or activation of the JNK and p38 MAPK pathways. Our results demonstrate the feasibility in enhancing the efficacy of currently used drugs to selectively kill cancer cells using peptides derived from pro-apoptotic caspase substrate fragments.
Introduction
Tumors are diverse and heterogeneous, but all share the ability to proliferate without control. Deregulated cell proliferation coupled with suppressed apoptotic sensitivity constitutes a minimal requirement upon which tumor evolution occurs (Evan and Vousden, 2001; Danial and Korsmeyer, 2004) . One of the most commonly used treatments is chemotherapy, which frequently uses chemical compounds that induce DNA damage, such as cisplatin, adriamycin or mitoxantrone. Anticancer agents are effective only when tumors cells are more readily killed than the surrounding normal tissue. If the efficacy of these agents is partly determined by their ability to induce apoptosis, then tumors cells must be more susceptible to apoptosis than the normal tissue from which they arose. Interestingly, it has been shown that proto-oncogenes, such as Myc, have the ability to increase cellular chemosensitivity (Prendergast, 1999; Seoane et al., 2002) , indicating that specific deregulated pathways in tumor cell could be targeted to increase chemotherapy efficacy. We have recently demonstrated that RasGAP, a regulator of Ras and Rho GTP-binding proteins, is an unconventional caspase substrate because it can induce both anti-and proapoptotic signals, depending on the extent of its cleavage by caspases Widmann, 2001, 2002a, b) . At low levels of caspase activity, RasGAP is cleaved at position 455, generating an N-terminal fragment (fragment N) and a C-terminal fragment (fragment C) . Fragment N appears to be a general blocker of apoptosis downstream of caspase activation Widmann, 2001, 2002b) . At higher levels of caspase activity, the ability of fragment N to counteract apoptosis is suppressed when it is cleaved at position 157. This latter cleavage event generates two fragments, N1 and N2, that in contrast to fragment N potently sensitizes HeLa cells toward cisplatin-induced apoptosis (Yang and Widmann, 2001) . In the present study we show that a cell permeable peptide derived from the N2 fragment of RasGAP specifically sensitizes cancer cells to three different genotoxins commonly used in chemotherapy.
Results

RasGAP fragment N2 potentiates the apoptotic response induced by a variety of genotoxins
We have recently shown that fragment N2 potently sensitized the ability of cisplatin to kill the HeLa tumor cell line (Yang and Widmann, 2001) . To assess whether fragment N2 could potentiate the apoptotic response induced by other genotoxins, HeLa cells, expressing or not fragment N2, were subjected to increasing concentrations of adriamycin and mitoxantrone (and cisplatin as control). Figure 1 shows that the presence of fragment N2 rendered HeLa cells at least 10 times more sensitive than control cells towards the various drugs.
This result indicates that fragment N2 is a broadspectrum genotoxin sensitizor.
Identification of a minimal genotoxin-sensitizing sequence within fragment N2
Fragment N2 is a 36 kDa protein, which makes it difficult to synthesize chemically. Characterization of a shorter sequence that would still bear the genotoxinsensitizing ability is a critical step in the process of developing a therapeutical tool from fragment N2. In order to assess whether such a short sequence could be isolated, we generated a series of truncated versions of fragment N2 (Figure 2a ) and determined their ability to potentiate cisplatin-induced apoptosis in HeLa cells (Figure 2b ). Fragment N2 contains two SH2 domains and one SH3 domain (Figure 2a) . We first determined which of these domains contained the proapoptotic activity of fragment N2. HeLa cells were transfected with the plasmids encoding the various SH domains, in the presence or in absence of 0.15 mM cisplatin, a concentration at which the difference in sensitivity towards the drug between cells expressing or not fragment N2 is maximal (see Figure 1 ). HeLa cells transfected with an empty construct or with a construct encoding the SH2 domain only were not sensitized towards cisplatin-induced death. In contrast, cells expressing the constructs containing the SH3 domain had an increased sensitivity towards cisplatin-induced apoptosis (Figure 2b, upper panel) . The inability of the SH2 domain alone to potentiate the cell death in HeLa We next generated progressive truncations in the SH3 domain in an attempt to identify a minimal genotoxinsensitizing sequence. All these constructs (see Figure 2a) , including the shortest one (317-326) that codes for a 10 amino-acid long peptide, potentiated the ability of cisplatin to kill HeLa cells (Figure 2b, lower panel) . These results suggest that the cell-death sensitizing property of fragment N2 does not require a complete SH domain but is mediated by a very short peptidic sequence.
The HIV-TAT 48-57 peptide conjugated with the 317-326 RasGAP sequence acts as a cell permeable genotoxinsensitizing peptide If a plasmid encoding amino acid 317-326 of RasGAP has the ability to sensitize cells towards apoptosis, a synthetic peptide corresponding to the 317-326 should also display this activity provided that it can penetrate cells. It has been demonstrated that the addition of a short sequence derived from the HIV-TAT protein (HIV-TAT 48-57 ) allows polypeptides to accumulate efficiently in cells (Schwarze et al., 1999) . We therefore synthesized a peptide containing the amino acids 317-326 of RasGAP covalently bound to the amino acids carrier peptide HIV-TAT [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] . Two glycine residues were inserted between the TAT and RasGAP sequences as spacer to allow flexibility. As a mean to assess the cellular uptake of this peptide (thereafter called TATRasGAP 317-326 peptide), we labeled it with the FITC fluorophore. The labeled peptide was incubated with four different tumor cell lines: a human adenocarcinoma from cervix (HeLa cells), a human osteosarcoma (U2OS cells), a breast cancer cell line (MCF-7 cells) and a human malignant mesothelomia (H-Meso-1 cells) and two non cancer cell lines (HaCat human skin keratinocyte cell line and the HUV-EC-C human umbilical endothelial cells). As shown in Figure 3 , the TATRasGAP 317-326 peptide efficiently entered all these cell lines. No difference in translocation of the peptide was noted between the noncancer cells and the cancer cells. We then determined whether the TAT-RasGAP 317-326 peptide sensitized specifically tumor cells towards genotoxin-induced apoptosis. We first assessed the sensitivity of the cancer cell lines towards increasing concentrations of the three genotoxins (data not shown). This allowed us to determine the sublethal concentrations of the genotoxins for each cell lines tested. Figure 4a shows that the TAT-RasGAP 317-326 peptide, but not the control HIV-TAT 48-57 peptide lacking the RasGAP sequences, rendered all the tested cancer cell lines sensitive to doses of cisplatin, adriamycin, and mitoxantrone that did not, or only marginally, induce apoptosis in control conditions. In contrast, the apoptotic response induced by cisplatin, adriamycin and mitoxantrone in the two noncancer lines was unaffected by the presence of the peptides (Figure 4b ).
We have therefore identified a minimal synthetic peptide able to specifically enter and sensitize cancer cells towards genotoxin-induced apoptosis.
NFkB and the SAPK pathways are not involved in the sensitizing properties of TAT-RasGAP 317-326.
As a Ras modulator, RasGAP could affect some of the Ras-dependent pathways controlling cell death, such as the Ras-PI3K-Akt-NFkB pathway (Datta et al., 1999) . We therefore assessed whether modulation of NFkB activity participates in the sensitization effect mediated by TAT-RasGAP 317-326. As shown in Figure 5a , NFkB was activated in U2OS cells after a treatment with (Beg and Baltimore, 1996; Van Antwerp et al., 1996; Wang et al., 1997) , but can also be required for the induction of apoptotic responses in some situations (Ryan et al., 2000) . To determine whether activation of NFkB by TAT-RasGAP 317-326 was required for its sensitization function, a nondegradable form of IkB (IkBaDN2) was expressed in cells. As expected, this construct efficiently prevented the activation of NFkB by cisplatin and TAT-RasGAP [317] [318] [319] [320] [321] [322] [323] [324] [325] [326] (Figure 5b ). IkBaDN2 slightly increased the apoptotic response mediated by cisplatin (Figure 5c ). The potency of TAT-RasGAP 317-326 to sensitize U2OS cells to cisplatin-induced apoptosis was however unaffected by the NFkB inhibitor (Figure 5c ). These results indicate that The stress-activated protein kinases (SAPKs) -the JNKs and the p38 MAPKs -have been implicated in the apoptotic response induced by various stimuli (Jarpe et al., 1998) . Figure 6 shows that neither the control HIV-TAT 48-57 peptide nor the TAT-RasGAP 317-326 sensitizing peptide activated these MAPK pathways. These peptides were also not able to increase the ability of cisplatin to stimulate the JNK or the p38 MAPKs (Figure 6 ). These results indicate that the stressactivated MAPK pathways are not implicated in the capacity of TAT-RasGAP 317-326 to sensitize cancer cells to genotoxins.
Discussion
Chemotherapy, alone or in combination with other treatments (e.g. radiotherapy), is currently one the most common and efficient therapeutical tool to fight cancers. The efficacy of the drugs used in chemotherapy to treat cancers (the genotoxins) relies on their ability to kill tumor cells. There is however a limitation in the use of genotoxins that comes from the fact that they can also adversely affect normal cells. The challenge for the clinicians is therefore to choose the doses of genotoxins that are high enough to eliminate the tumors but not so high as to induce severe side effects in the patients. Improving the selectivity of the genotoxins towards tumor cells would obviously augment the efficacy of chemotherapeutic treatments.
Recently, methods have been developed for delivery of exogenous proteins into living cells with the help of membrane permeable carrier peptide such as HIV-TAT 48-57 . These methods have been used to allow internalization of various proteins or peptides and to modulate cellular processes such as cell division, cell migration and apoptosis (Lindsay, 2002) . HIV-TAT [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] has also been shown to allow the delivery of biological active proteins into mouse tissues (Schwarze et al., 1999; Borsello et al., 2003) . In the present study, we have identified a 10 amino-acid sequence derived from RasGAP (RasGAP [317] [318] [319] [320] [321] [322] [323] [324] [325] [326] ) that sensitized HeLa cells to cisplatin-induced apoptosis. A chimeric peptide made of HIV [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] and RasGAP 317-326 (TAT-RasGAP 317-326 ) efficiently penetrated tumor cells and favored their death in response to various genotoxins. TAT-Ras-GAP 317-326 also readily entered non-cancer cells but it did not modulate their sensitivity to genotoxins.
Cell survival and apoptosis are regulated by various intracellular signaling molecules. An important factor that is often implicated in the regulation of cell death is the NFkB transcription factor. Depending on the cellular system and the apoptotic stimuli, NFkB can either participate in the induction of cell death or function as a blocker of apoptosis (Barkett and Gilmore, 1999) . NFkB was weakly activated by cisplatin or the TAT-RasGAP 317-326 peptide. This weak activation is presumably a response of the stressed cells to augment their resistance to apoptosis because blocking NFkB activation slightly augmented their sensitivity to genotoxin-induced death. However, the extent of genotoxin sensitization mediated by the TAT-Ras-GAP 317-326 peptide was unaffected by the blockage of the NFkB pathway. Therefore, modulation of NFkB is apparently not involved in the sensitization properties of TAT-RasGAP 317-326 .
Stress-activated MAPK pathways control cell survival and apoptosis in numerous systems (Jarpe et al., 1998) . However, TAT-RasGAP 317-326 does neither activate these pathways nor modulate their activity when cells are stimulated with genotoxins ( Figure 6 ). This indicates that the mechanism used by TAT-RasGAP 317-326 to increase the sensitivity of tumor cells to genotoxins does not employ the stress-activated MAPK pathways. Additional work is required to further decipher the molecular mechanisms used by TAT-RasGAP 317-326 to sensitize cells to genotoxins.
In conclusion, TAT-RasGAP 317-326 favors apoptosis of tumor cells in response to various genotoxins. Importantly, this peptide does not sensitize normal noncancer cells to cell death. This raises the possibility that the TAT-RasGAP 317-326 peptide or components with similar properties could be used in patients to enhance the effect of genotoxins specifically in tumors cells.
Materials and methods
Cells and transfection
HeLa and MCF-7 cells were maintained in RPMI 1640 (Sigma; cat. no. 8758) containing 10% newborn calf serum (Sigma; cat. no. N4637) at 371C and 5% CO 2 . U2OS cells were maintained in DMEM (Sigma; cat. no 5796) containing 15% foetal calf serum (Sigma; cat. no F7524) at 371C and 5% CO 2 . H-Meso-1 cells were maintained in RPMI 1640 containing 10% foetal calf serum at 371C and 5% CO 2 . HUV-EC-C cells were maintained in human endothelial SFM medium (Gibco; cat. no. 11111-044) complemented with 10% foetal calf serum, 20 ng/ml of basic fibroblast growth factor (Gibco; cat. no 13256-029), 10 ng/ml of epidermal growth factor (Gibco; cat. no. 13247-051), 10 mg/ml of fibronectin (Gibco; cat. no. 33016-015) at 371C and 5% CO 2 . HaCat cells were maintained in keratinocyte SFM medium containing epidermal growth factor 1-53 and extract from bovine pituitary gland (Gibco; cat. no. 17005-075) at 371C and 5% CO 2 . HeLa cells were transfected as described previously (Yang and Widmann, 2001) . Genotoxin treatment was performed in six-well plates. The cells were split the day before the treatment at a concentration of 2.5 Â 10 5 cells/well. U2OS cells were transfected in six-well plates using the calcium/phosphate precipitation procedure (Jordan et al., 1996) . Briefly, plasmids were diluted in 90 ml H 2 O, mixed with 10 ml CaCl 2 2.5 M and incubated 10 min at room temperature. Then, 100 ml of HEP solution (280 mM NaCl, 10 mM KCl, 1.5 mM Na 2 HPO 4 , 12 mM D-glucose, 50 mM HEPES) was rapidly mixed with the DNA solution, incubated at room temperature for exactly 1 min, and finally transferred to the cell culture medium. After 8 h at 371C and 5% CO 2 , the medium was replaced with fresh culture medium and the cells were further incubated for 16-24 h before being analysed.
Chemicals
Cisplatin and mitoxantrone were from Sigma (cat. no. P4394 and no. M6545, respectively). Cisplatin was diluted in DMSO at a final concentration of 100 mM and stored at À201C. Mitoxantrone was diluted in ethanol 100% at a final concentration of 10 mM and stored at À801C. Adriamycin was from Calbiochem (cat. no. 324380). It was diluted in water at a final concentration of 10 mM and stored at À201C. Hoechst 33342 was from Roche (cat. no. H-1399) . It was diluted in water at a final concentration of 10 mg/ml and stored at 41C in the dark.
Peptide synthesis and labeling.
The HIV-TAT 48-57 (GRKKRRQRRR) and TAT-Ras-GAP 317-326 (GRKKRRQRRRGGWMWVTNLRTD) peptides were synthesized at the Institute of Biochemistry, University of Lausanne, Switzerland using FMOC technology, purified by HPLC and tested by mass spectrometry.
Fluorescein isothiocyanate (FITC)-labeling was performed on the sequence b-alanine-GRKKRRQRRRGGWMW VTNLRTD, whose side chain Fmoc-protected amino acids were Arg(bpf), Lys(Boc), Gln(Trt), Trp(Boc), Thr(tBu), Asn(Trt), and Asp(OtBu). The peptide was synthesized stepwise on 0.2 mmol Rink Amide AM resin using Fmoc chemistry. The synthesis was monitored by ninhydrin test. After the coupling of b-alanine, the Fmoc group was removed with 20% piperidine in dimethylformamide (DMF). At this stage, a fluorescein group was conjugated to the N-terminus of the peptide with FITC (five-fold excess over the substitution of the resin in 4 ml DMF and 1 ml N-ethyldiisopropylamine) to form the fluorescein-derivated peptide.
Peptides were dissolved in deionized water at a final concentration of 1 mM and stored at À201C until further use.
Plasmids
The extension dn3 in the name of a plasmid indicates that the backbone plasmid is the expression vector pcDNA3 (Invitrogen). All the constructs were tagged with the HA sequence (MGYPYDVPDYAS) at the N amino-terminal end. Plasmid N2.dn3 encodes the human RasGAP fragment N2, plasmid SH2-SH3.dn3 encodes human RasGAP amino acids 158-361, plasmid SH2.dn3 encodes human RasGAP amino acids 158-277, plasmid SH3.dn3 encodes human RasGAP amino acids 279-361. Plasmid IkBaDN2 encodes a form of IkBa that blocks the activation of NFkB (Yang and Widmann, 2002b) . Plasmid pEGFP-C1, encoding the GFP protein, was from Clontech. pRL-TK, a vector encoding the Renilla reniformis luciferase, was from Promega. prLUC is a reporter plasmid bearing the firefly luciferase cDNA under the control of NFkB-responsive elements (Yang and Widmann, 2001 ).
Apoptosis measurements
Apoptosis was determined by scoring the number of cells displaying pycnotic nuclei. Nuclei of live cells were labeled with Hoechst 33342 (10 mg/ml final concentration) for about 5 min and the cells were then analysed (at least 400 cells per condition) using an inverted Leica DMIRB microscope equipped with fluorescence and transmitted light optics. Assessment of apoptosis was performed one day after the transfection or treatment of the cells. In experiments involving transfected cells, pEGFP-C1 was included in the transfection solution to label the transfected cells with GFP. In this case, the extent of apoptosis was assessed in the transfected cells only.
Luciferase reporter assay
Luciferase assay was performed using the Dual-Luciferase s Reporter Assay from Promega (cat. no. E1910). The cells were lysed from a six-well plate using 100 ml of PLB lysis buffer provided from the Promega's kit and incubated 30 min on ice. The lysate was then cleared by centrifugation at 16 000 g for 15 min. The firefly luciferase activity was recorded by mixing 20 ml of the lysate with 25 ml of the LARII Reagent and the Renilla luciferase activity was recorded by adding to the previous mix 25 ml of the Stop and Glo Reagent. For each measurement, light emission was quantified during 12 s using a Lumat LB 9501 luminometer (Berthold Technologies, Zurich, Switzerland).
Western blot analysis
Cells were lysed in lysis buffer (25 mM HEPES, 300 mM NaCl, 1.5 mM MgCl 2 , 0.2 mM EDTA, 0.1 mM Na 3 VO 4 , 1% Triton X-100), Complete EDTA-free Protease Inhibitor Cocktail Tablets (Roche; cat. no. 1873580). Proteins were separated on SDS-PAGE and blotted onto nitrocellulose membranes (BioRad; cat. no. 162-0115). Thereafter, membranes were blocked with TBS (18 mM HCl, 130 mM NaCl, 20 mM Tris), 5% non-fat dry milk for 30 min at room temperature and incubated overnight with the appropriate primary antibody. These antibodies were detected by Alexa Fluor 680 conjugated secondary antibodies (Molecular Probes; cat. no. A21109) diluted 1 : 2500 in TBS, 5% non-fat dry milk and subsequently visualized with the Odyssey infrared imaging system (Licor, Homburg, Germany). The primary antibody against phospho-p38 (Cell Signaling Technology; cat no. 9211L) was diluted 1 : 500 in 5% BSA in TBS. The primary antibody against phospho-JNK (Cell Signaling Technology; cat no. 9551L) was diluted 1 : 1000 in TBS, 5% BSA. Quantitation was performed using the Odyssey infrared imaging software.
Statistical analysis
All the statistical analyses were performed with Microsoft Excel (XP edition) using the student's t-test.
